Evolving Role of IMDC Risk Stratification in First-Line Treatment Selection

Dr. Monty Pal discusses the historical role of the International Metastatic Renal Cell Database Consortium (IMDC) risk criteria in guiding treatment decisions for advanced renal cell carcinoma (RCC) and explains why its influence has evolved in the current therapeutic landscape. He reviews the clinical factors included in the IMDC model and reflects on how evidence from pivotal immunotherapy trials has reshaped his interpretation of risk-based treatment selection. Dr. Pal explains that although IMDC risk stratification remains a useful clinical tool, he places greater emphasis on individual patient characteristics and the broader clinical context rather than relying exclusively on risk category. He also highlights important considerations when selecting between dual immunotherapy and immunotherapy plus tyrosine kinase inhibitor combinations for patients with favorable-risk disease, emphasizing differences in response rates and the need to tailor treatment decisions based on each patient's disease characteristics, treatment goals, and anticipated clinical benefit.